Abstract. Highly malignant gliomas are characterized by pronounced intra- and intertumoral heterogeneity. On the genetic level, this heterogeneity may be caused by spontaneous mutation events, but recent studies have reported distinct mutational signatures that may be caused by an enzyme family with cytidine desaminase activity, the apolipoprotein B mRNA editing enzyme catalytic polypeptide-like (APOBEC) proteins. Among these, APOBEC3B contributes to tumor progression in a variety of types of tumor, including breast cancer. In the present study, the expression of APOBEC3B was detected at the mRNA and protein levels in solid human glioma tissue and human glioma cell lines. In vitro, treatment with temozolomide, the most commonly used chemotherapeutic in glioma therapy, induced APOBEC3B expression. Furthermore, the knockdown of APOBEC3B by clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 resulted in reduced proliferation and enhanced chemosensitivity of glioma cells. Thus, APOBEC3B contributes to glioma progression and may be a future target for therapeutic intervention.

Introduction

Glioblastomas are highly malignant brain tumors that have a poor prognosis for patients despite advanced surgery and subsequent aggressive treatment with combined radiotherapy and chemotherapy (1). Over 90 years ago, Bailey and Cushing established the term glioblastoma multiforme (2) for the astrocytoma World Health Organization (WHO) grade IV, paying tribute to the pronounced heterogeneity of this type of tumor. This heterogeneity has been observed and investigated in a variety of aspects of glioblastoma biology, and attributed to the differential response of patients to therapy (3,4). Cell cycle control and DNA repair mechanisms have been identified as key aspects at the evolutionary origin of the pronounced inter- and intratumoral genetic heterogeneity of gliomas, amongst others (5,6). However, a recent study indicated an important role of the apolipoprotein B mRNA editing enzyme catalytic polypeptide-like (APOBEC) enzyme family in genetic instability and heterogeneity, as specific patterns of DNA mutagenesis have been observed in various types of human tumors (7). The evolutionarily highly conserved APOBEC enzyme family members have cytidine desaminase activity, by which they exert post-transcriptional editing of the mRNA by converting cytosine to uracil; for example, in the mRNA of apolipoprotein B and neurofibromin (8). Certain APOBEC family members also support the innate immune system by editing the viral genome, particularly the genome of retroviruses like the human immunodeficiency virus HIV (9). In cancer, APOBEC family members are key players in the induction of cancer evolution and heterogeneity (10). In particular, APOBEC3B has been identified as the major cause for typical mutagenesis patterns, for example in breast (11), bladder, cervix, head and neck, and lung cancer (12). Although a recent study has addressed a putative APOBEC enzyme-caused mutational signature in gliomas (13), to the best of our knowledge, there is no information available on the APOBEC3B protein in human gliomas. Thus, the present study investigated the expression and functional role of APOBEC3B in human glioma tissue and cell lines.

Materials and methods

Tissue and cell lines. Glioma samples of different malignancy grades were obtained at the Department of Neurosurgery, University Medical Center Schleswig-Holstein UKSH (Kiel, Germany) in accordance with the Declaration of Helsinki (1975) with approval from the Ethics Committee of the University of
Kiel (Kiel, Germany) and after written informed consent was obtained from the donors (file reference, D536/15). Diagnosis was established by a pathologist and malignancy grades were determined according to the WHO classification system. Non-neoplastic brain tissue samples were obtained from the Institute of Legal Medicine, University Kiel. Glioma cell lines LN229, A172, T98G and U251MG were purchased from the European Collection of Cell Cultures (Salisbury, UK) or the American Type Culture Collection (Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle medium (DMEM) plus 10% fetal bovine serum (FBS) (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Cells were routinely checked for Mycoplasma contamination using bisbenzimide staining, and for identity/purity by short tandem repeat profiling at the Department of Forensic Medicine, University of Kiel where the Powerplex HS Genotyping kit (Promega Corporation, Madison, WI, USA) and a 3500 Genetic analyzer (Thermo Fisher Scientific, Inc.) were employed.

**Cell stimulations and clustered regularly interspersed short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing.** In order to analyze the regulation of CRISPR/Cas9 silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing. In order to analyze the regulation of palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) silencing.

For CRISPR/Cas9 silencing, 5.0x10^4 LN229 cells/well were seeded in six-well plates and transfected with 1 µg of the APOBEC3B Double Nickase plasmid (cat. no. sc-401700-NIC) or the corresponding Double Nickase Control plasmid (cat. no. sc-437281) using the UltraCruz Transfection reagent (from Santa Cruz Biotechnology, Inc., Dallas, TX, USA) for 24 h. Following the manufacturer’s protocol, selection was performed with puromycin (Invitrogen; Thermo Fisher Scientific, Inc.), and clones were selected and analyzed using RT-qPCR, ICC and western blot analysis.

**RT-qPCR.** For mRNA expression analysis, cells were harvested and tissues were homogenized using QIAshredder Lysis reagent (Qiagen GmbH, Hilden, Germany) and total RNA was isolated according to the manufacturer’s protocol. Genomic DNA was digested by RNase-free DNase (1 U/µl; Promega Corporation) and cDNA was synthesized using RevertAid™ H Minus M-MuLV Reverse Transcriptase (200 U/µl; Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol. RT-qPCR was performed as previously described (14) using the following TaqMan Primer probes (Applied Biosystems; Thermo Fisher Scientific, Inc.): hGAPDH (Hs99999905_m1) and hAPOBEC3B (Hs00358981_m1). Samples were analyzed in duplicates and cycle threshold (Cq) values were measured with the ABI PRISM 7500 Sequence Detection system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions were as follows: 2 min at 50°C and 10 min 95°C, followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C. Cq values were used to calculate ΔCq values [Cq(APOBEC3B) - Cq(GAPDH)]. Due to logarithmic reaction process, a ΔCq value of 3.33 corresponds to one magnitude lower gene expression compared with that of GAPDH. For stimuli-induced mRNA regulation, ΔΔCq values were calculated as follows: \( \Delta \Delta Cq = 2^{-(\Delta Cq(stimulus-temozolomide) - \Delta Cq(control-DMSO))} \).

**For statistical analysis, undetectable samples were calculated as the anticipated maximum cycle number-Cq (GAPDH).**

**Immunohistochemistry and ICC.** Immunohistochemistry was performed as previously described (15). Briefly, cryo-stat sections from three different fresh-frozen glioblastoma samples were fixed in ice-cold acetone/methanol (1:1) for 10 min at room temperature and washed with Tris-buffered saline with 0.1% Tween (TBS-T). The samples were then blocked for autofluorescence with 1% Sudan black (in 70% ethanol) for 1 h at room temperature and for unspecific binding with 0.5% glycine/0.5% bovine serum albumin (SERVA Electrophoresis GmbH, Heidelberg, Germany) in TBS and incubated with the primary antibodies overnight at 4°C. Subsequently, the samples were washed with TBS-T and incubated with the secondary antibodies for 1 h at 37°C. The samples then were washed again with TBS-T, incubated with 4',6-diamidino-2-phenylindole (DAPI; 1:30,000; Invitrogen; Thermo Fisher Scientific, Inc.) for 30 min at room temperature to counterstain the nuclei, washed with TBS-T, and embedded with Shandon™ Immuno-Mount™ (Thermo Fisher Scientific, Inc.). The primary antibodies were as follows: Anti-human APOBEC3B (rabbit polyclonal; 1:100; cat. no. TA349029; OriGene Technologies, Inc., Rockville, MD, USA); anti-human glial fibrillary acidic protein (GFAP; mouse monoclonal; 1:100; cat. no. M0761; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA); anti-human platelet endothelial cell adhesion molecule (Pecam-1; goat polyclonal; 1:100; cat. no. sc-1506; Santa Cruz Biotechnology, Inc.). The secondary antibodies were as follows: Donkey anti-rabbit IgG Alexa Fluor 555 (cat. no. A-31572); donkey anti-mouse IgG Alexa Fluor 488 (cat. no. A-21202); and donkey anti-goat IgG Alexa Fluor 488 (cat. no. A-11055) (all 1:1,000; Invitrogen; Thermo Fisher Scientific, Inc.).

For immunocytochemical analysis, cells were seeded on glass cover slips (2.0x10^4 cells/cover slip) and grown for 1 day (or for the subsequent treatment period). The cells were fixed with ice-cold acetone-methanol for 10 min at room temperature, blocked with 0.5% glycine/0.5% bovine serum albumin in PBS for 1 h at room temperature and incubated with anti-human APOBEC3B (rabbit polyclonal; 1:100) overnight at 4°C. The cells were then washed with PBS +0.1% Tween (PBS-T; 3X) and incubated with donkey anti-rabbit IgG Alexa Fluor 555 (Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C for 1 h. Subsequently, the cells were washed with PBS-T (3X), the nuclei were counterstained with DAPI for 30 min at room temperature, and the slips were embedded using Immuno-Mount.

The slides were viewed and imaged using a Zeiss Axiosvert 200 M fluorescence microscope (Zeiss AG, Oberkochem, Germany) at x400 and x630 magnification. In order to compare
differences in the expression of APOBEC3B, equal exposure times were used.

Western blot analysis. For western blot analysis, cells were lysed (50 mM Tris, 100 mM NaCl, 5 mM EDTA, 1% Triton X-100, pH 7.8), and protein content was measured using the Bradford protein assay. Protein content was adjusted to 5 μg/20 μl with sample buffer (10% glycerin, 0.4% SDS, 50 mM dithiothreitol in 75 mM Tris), and samples were separated by SDS-PAGE (10% acrylamide gels, 5 μg/lane) and blotted onto a polyvinylidene fluoride membrane. The membrane was blocked with 5% skim milk powder in TBS-T for unspecific binding for 1 h at room temperature and incubated with anti-human APOBEC3B (rabbit polyclonal; 1:250) overnight at 4°C. Subsequently, the membrane was washed with TBS-T (3X) and incubated with horseradish peroxidase-conjugated secondary antibody overnight at 4°C (goat anti-rabbit; 1:30,000; cat. no. sc-2004; Santa Cruz Biotechnology, Inc.). The membrane was then washed again with TBS-T, followed by chemoluminescence signal detection (Immobilon; Merck KGaA, Darmstadt, Germany) using a Peqlab Fusion camera (Peqlab Biotechnologie GmbH, Erlangen, Germany). Blots were reblotted following stripping (ReBlot Plus Strong Antibody Stripping solution; Merck KGaA) for GAPDH (primary antibody mouse anti-human; 1:250; cat. no. sc-47724; goat anti-mouse horseradish peroxidase-conjugated secondary antibody; 1:30,000; cat. no. sc-2005; from Santa Cruz Biotechnology, Inc.) in order to compare loading using the same protocol aforementioned.

Proliferation assay. In order to compare the proliferation of LN229 and APOBEC3B CRISPR/Cas9 knockdown clones with that of control clones, 2.5x10^4 cells/well were seeded in 6-well plates in triplicates, and cultured for 24, 48, 72 and 96 h. Cells were then washed with PBS, harvested, and analyzed using a CyQUANT™ cell proliferation assay (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. As an internal standard, 2.5x10^4 cells (APOBEC3B and control clones) were lysed and measured, and fluorescence signals were normalized to these samples.

Caspase 3/7 assay. In order to analyze the influence of APOBEC3B on the sensitivity of cells to temozolomide, the most common chemotherapeutic agent used in glioblastoma therapy, 3.0x10^5 APOBEC3B clone cells or control clone cells were seeded in T25 flasks, and cultured for 24 h. Subsequently, the medium was replaced by fresh DMEM with 10% FBS and different concentrations of temozolomide (or an equal volume of DMSO as a solvent control), and the cells were treated for a further 48 h. Caspase 3/7 activity was measured as previously described (16).

Statistical analysis. All values are presented as the mean ± standard deviation. Expression values from tumor samples were compared with non-neoplastic brain tissue samples using one-way analysis of variance (ANOVA) with Dunnet’s multiple comparison post hoc test. To analyze induction of APOBEC3B expression, a paired Student’s t-test was used. For statistical analysis of biological effects of APOBEC3B silencing (proliferation and caspase 3/7 assays) one-way ANOVA with Bonferroni’s multiple comparison post hoc test was used to compare control clones with APOBEC3B knockdown clones at different time points (proliferation) or upon different temozolomide treatment doses (caspase 3/7 assay). P<0.05 was considered to indicate a statistically significant difference.

Results

Expression and drug-induced regulation of APOBEC3B in gliomas. As the initial step, the expression and cellular localization of APOBEC3B in solid human astrocytoma samples of different malignancy grades, as well as in commercial glioblastoma cell lines, were investigated. Additionally, the regulation of the amounts of APOBEC3B mRNA and protein was analyzed in temozolomide-treated glioblastoma cells.

APOBEC3B was expressed in all of the glioma samples in considerable amounts (mean ΔCq value range, 8.0-9.0 for astrocytoma grade I-IV; grade IV astrocytoma is also known as glioblastoma). Compared with the normal brain control samples, APOBEC3B was significantly overexpressed in glioblastoma tissue. The mean ΔCq values were 11.2 for the normal brain samples, and 8.4, 9.1, 8.2 and 8.0 for grade I-IV astrocytoma samples, respectively (Fig. 1, left). A ΔCq value of 3.33 corresponds to one magnitude lower gene expression compared with that of the reference marker GAPDH. In the glioblastoma samples, APOBEC3B was expressed in GFAP-positive astrocytic tumor regions and was detected near to Pecam-1-positive tumor vessels, but was not co-stainable with MIB-1 (antigen Ki-67), which is a marker of active proliferating cells (Fig. 1, right).

With the exception of the U251MG cell line, APOBEC3B was evidently detectable in the glioblastoma cell lines investigated (A172, LN229, T98G and U251MG) at the transcriptional level, as determined using RT-qPCR (Fig. 2, left). The mean ΔCq values were as follows: 8.4±0.7 (A172), 6.7±0.2 (LN229), 6.8±1.1 (T98G) and 18.5±3.0 (U251MG) (n=4 independent experiments). Furthermore, APOBEC3B expression was evaluated at the translational level using ICC in the LN229, T98G and U251MG cell lines (n=2 independent experiment; Fig. 2, right). When stimulating LN229 glioblastoma cells with temozolomide (100 μg/ml for 10 days), the standard chemotherapeutic drug used in glioblastoma treatment, APOBEC3B mRNA expression was increased up to 9-fold (range, 3.5 to 9.2-fold; mean, 6.1±1.9-fold; Fig. 3, left; n=8 independent experiments; P<0.05) of that in the DMSO control group. In accordance with this, APOBEC3B protein was detectable in markedly higher amounts in the temozolomide-treated LN229 cells compared with those of the DMSO control-treated cells (Fig. 3, right; n=2 independent experiments).

Biological functions of APOBEC3B in glioblastoma. In order to investigate the biological functions of APOBEC3B in glioblastoma, stable APOBEC3B CRISPR/Cas9 knockdown LN229 clones were established. The knockdown efficiency was confirmed using RT-qPCR, western blot analysis and ICC. All methods demonstrated clearly diminished levels of APOBEC3B expression at the mRNA and protein levels. At the mRNA level (n=3) APOBEC3B expression was reduced to 1.7±0.8% in comparison with...
the corresponding control CRISPR/Cas9 clones (data not shown). At the protein level, evident reduced signals were observed in the western blot experiments (Fig. 4A) and no APOBEC3B signals in the APOBEC3B CRISPR/Cas9 knockdown LN229 clones were identified by ICC (equal exposure times, Fig. 4A).

Figure 1. Expression of APOBEC3B in solid human gliomas. Left: Transcription of APOBEC3B was analyzed in eight NB, six grade I astrocytoma, six grade II astrocytoma, five grade III astrocytoma and seven grade IV astrocytoma/GBM using RT-qPCR. In all of the investigated glioma samples, APOBEC3B mRNA was clearly detectable. In the grade IV tumors, the levels of mRNA expression were significantly higher compared with those in the non-neoplastic brain tissues. Black bars indicate mean values and a lower ΔCq value of 3.33 corresponds to a magnitude higher expression. In a number of the non-neoplastic brain tissue samples, APOBEC3B could not be detected (below detection limit); thus, a mean bar could not be included. Right: Expression and localization of APOBEC3B were analyzed using immunohistochemistry in the human glioblastoma samples. APOBEC3B (red) was detected on the protein level in GFAP-positive tumor regions (green), frequently in small cell clusters and in proximity to blood vessels (stained by Pecam-1; green), and co-localizing with MIB-1 (green), a marker of proliferating cells, was not evident. For negative control, primary antibodies were respectively omitted. Representative examples of three individual glioblastoma samples are shown at x630 magnification. *P<0.05, one-way analysis of variance followed by Dunnet’s multiple comparison test. APOBEC3B, apolipoprotein B mRNA editing enzyme catalytic polypeptide-like protein 3B; Cq, cycle of threshold; GBM, glioblastoma multiforme; GFAP, glial acidic fibrillary protein; MIB-1, made in Borstel-1; NB, normal brain; Pecam-1, platelet endothelial cell adhesion molecule; Sec ab, secondary antibody control.

Figure 2. Expression of APOBEC3B in human glioblastoma cell lines. APOBEC3B expression was analyzed on the mRNA (RT-qPCR, left) and protein (ICC, right) levels in human glioblastoma cell lines. Clearly detectable levels of mRNA expression were observed in the A172, LN229 and T98G cells, while APOBEC3B was hardly detected in the U251MG cells. At the protein level, APOBEC3B was exemplarily analyzed in the LN229, T98G and U251MG cells. Data are presented as the mean ΔCq values ± standard deviation from n=4 individual RNA preparations and exemplary results from n=2 individual immunostainings at x400 magnification. APOBEC3B, apolipoprotein B mRNA editing enzyme catalytic polypeptide-like protein 3B; Cq, cycle of threshold; Sec ab, secondary antibody control; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; ICC, immunocytochemistry.
Investigation of the proliferative potential of APOBEC3B CRISPR/Cas9 knockdown LN229 clones for ≤96 h compared with that of their control-transfected counterparts revealed that LN229 clones with diminished APOBEC3B

Figure 3. Regulation of APOBEC3B upon TMZ treatment in vivo. LN229 glioma cells were treated for 10 days with 100 µg/ml TMZ or equal volumes of the solvent DMSO as a control. Expression analysis using RT-qPCR (left, circles indicate independent experiments, black bar indicates mean value from n=8 independent experiments, *P<0.05; Student’s two-tailed t-test) and ICC (representative examples of n=2 independent stimulations) demonstrated a significant induction (mean, 6.1-fold) of APOBEC3B upon TMZ treatment. For the microscopic images, the same magnifications (x630) and exposure times were used. APOBEC3B, apolipoprotein B mRNA editing enzyme catalytic polypeptide-like protein 3B; Cq, cycle of threshold; DMSO, dimethylsulfoxide; IgG ctrl, IgG control; TMZ, temozolomide; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; ICC, immunocytochemistry.

Figure 4. Knockdown of APOBEC3B reduces proliferation and enhances sensitivity of cells to TMZ. (A) In LN229-derived CRISPR/Cas9 knockdown clones of APOBEC3B, expression levels of APOBEC3B were markedly reduced compared with the control clones, as shown by western blotting (detection of GAPDH served as the loading control) and ICC. For the microscopic images, the same magnifications (x400) and exposure times were used. (B) LN229-derived CRISPR/Cas9 knockdown clones of APOBEC3B proliferated less compared with the corresponding control clones in a time period of 48-96 h, as detected by measurement of the DNA content. *P<0.01, one-way analysis of variance followed by Bonferroni’s multiple comparison test. (C) When exposed to different concentrations of TMZ for 48 h, LN229 APOBEC3B-knockdown cells exhibited significantly higher levels of caspase 3/7 activity compared with those of the corresponding control clones upon 200 and 400 µg/ml TMZ treatment. **P<0.01 and ****P<0.0001, one-way analysis of variance followed by Bonferroni’s multiple comparison test. The levels of basic caspase 3/7 activity in DMSO-treated cells were not significantly altered in the APOBEC3B CRISPR/Cas9 clones, compared with those of the control clones. Data are presented as the mean values ± standard deviation of n=3 independent experiments. APOBEC3B, apolipoprotein B mRNA editing enzyme catalytic polypeptide-like protein 3B; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; TMZ, temozolomide; CRISPR, clustered regularly interspaced short palindromic repeats; Cas9, CRISPR associated protein 9.
expression were characterized by a reduction in proliferation levels (Fig. 4B; n=3 independent experiments; P<0.01 at 96 h). Furthermore, as demonstrated by caspase 3/7 activity, APOBEC3B CRISPR/Cas9 knockdown LN229 clones exhibited significantly higher levels of sensitivity to temozolomide treatment compared with those of the controls (Fig. 4C). Increasing concentrations of temozolomide (100-400 mg/ml; 48 h) yielded increasing levels of caspase 3/7 activity in the control cells; however, in the APOBEC3B knockdown clones, the concentration-dependent induction of the caspase 3/7 activity was significantly more prominent (200 µg/ml TMZ, P<0.01; 400 µg/ml TMZ, P<0.0001). The caspase 3/7 activity in DMSO-treated samples was not significantly different between the APOBEC3B and control CRISPR/Cas9 clones. Thus, APOBEC3B mediates proliferative and anti-apoptotic effects in human glioblastoma cells.

In summary, the APOBEC3B enzyme was evidently detectable in human glioma samples of different malignancy grades, and was observable in astrocytic tumor regions and nearby tumor vessels. Furthermore, the APOBEC3B enzyme was inducible upon temozolomide treatment, and mediated proliferative and anti-apoptotic effects in human glioblastoma cells.

Discussion

A previous study has demonstrated that members of the APOBEC family may cause a characteristic pattern of mutations in a several types of cancer (7). Apart from their physiological role in mRNA editing, this enzyme family has important functions in the innate immune response to retroviruses and retrotransponsons, and may also contribute to tumor heterogeneity and progression via its DNA-desaminase activity (9,10). In the present study, it was demonstrated that APOBEC3B, a member of the APOBEC family, was overexpressed in glioblastoma (WHO grade IV), and was identified in astrocytic tumor regions and nearby tumor vessels. To date, APOBEC3B has only been detected in human leptomeninges and meningioma, to the best of our knowledge (17). However, Talagas et al (18) reported that certain oligodendroglial intracranial tumors that do not exhibit lp/19q deletions are characterized by various other mutations, including a homozygous deletion at 22q13.1 (APOBEC3B gene). To the best of our knowledge, there is no data regarding on the role of APOBEC3B in astroglial tumors to date. Focusing on another APOBEC family member in astroglial tumors, a recent study indicated an important role for APOBEC3G in mesenchymal glioma, a highly malignant brain tumor type (19). APOBEC3G knockdown attenuated the proliferation and invasion of glioblastoma cell lines by influencing the transforming growth factor (TGF)-β-signaling pathway via smad2, which resulted in decreased expression levels of proteins, including thrombospondin-1 and matrix-metalloproteinase-2 (19). However, the exact mechanism by which APOBEC3G regulates the TGF-β pathway remains unclear. Notably, Wang et al (20) revealed that APOBEC3G is upregulated in human astrocytoma (U87MG) cells by stimulation with different interferons, interleukin-1 and tumor necrosis factor. In contrast, other cytokines, including interleukin-4 or -6 and particularly TGF-β did not induce APOBEC3G expression. In the present study, expression of APOBEC3B was induced in cultured glioblastoma cells by temozolomide, the most commonly used chemotherapeutic in glioma therapy. Particularly in light of the proliferative and anti-apoptotic effects of APOBEC3B demonstrated in the present study, this induction may also influence the progression of glioma.

APOBEC3B is known to be involved in several types of cancer (12,21-27) and the results of the present study suggest that APOBEC3B may serve a more prominent role in brain cancer progression than previously assumed. Taking into account that Periyasamy et al (28) demonstrated that p53 regulates the expression of APOBEC3B in order to limit its potential mutagenic activity, the results of the present study are interesting. Glioblastoma are well known to be characterized by multiple mutations or allelic loss of the p53 tumor suppressor gene (3), and the A172, LN229, U251MG and T98G glioblastoma cell lines used in the present study exhibit nonsense or small frameshift mutations of the p53 gene [A172: p53 gene position 242, wt TGC, mut TTC (29); LN229: p53 gene position 164, wt AAG, mut GAG; U251MG: p53 gene position 273, wt CTG, mut CAT; and T98G: p53 gene position 237, wt ATG, mut ATA (30)]. As mutations or loss of the p53 gene result in elevated levels of APOBEC3B expression followed by increased levels of desaminase activity in cancer cells (28), the detectable amounts of APOBEC3B in glioblastoma cells may also be a consequence of p53 mutations. However, this paradigm does not apply absolutely as the U251MG cells were characterized by low levels of APOBEC3B expression (mean ΔCq, 18.5) in the present study, and this cell line also contains p53 point mutations. APOBEC3B expression has been demonstrated to be regulated by other mechanisms, for example by Myb-related protein B (encoded by MYB proto-oncogene like 2), which binds to the APOBEC3B promoter causing its transactivation (31), or by the classical nuclear (NF)-κB signaling pathway (32). Three NF-κB binding sites have been identified in the APOBEC3B promoter (32). In accordance with this, Leonard et al (33) demonstrated that protein kinase C activation causes the recruitment of RELB proto-oncogene NF-κB subunit (the gene encoding the transcription factor RelB), but not RELA proto-oncogene NF-κB subunit (the gene encoding the transcription factor p65), to the APOBEC3B promoter, indicating the involvement of the non-canonical NF-κB signaling.

With regards to its functional role, the results of the present study indicate that APOBEC3B mediates proliferative and anti-apoptotic effects in human glioblastoma cells, and, therefore, may promote glioma progression. However, a previous study reported that high levels of APOBEC3B expression causes hypersensitivity to small-molecule inhibitors that target the DNA damage response, suggesting that APOBEC3B overexpression also imparts targetable vulnerabilities upon cells (34).

In summary, APOBEC3B appears to serve a role in intracranial brain tumors, particularly in glioblastoma, contributing to glioma growth and heterogeneity by promoting the establishment of a mutational signature, and supporting glioma progression. APOBEC3B may therefore be a potential target for future therapeutic strategies against glioma.
Acknowledgements

The authors would like to thank Ms. Judith Becker, Ms. Martina Burmester and Ms. Sonja Dahle (all from the Institute of Anatomy, University Kiel, Germany) for expert technical assistance.

Funding

The present study was supported by a grant from the Familie Mehdorn Foundation and by the Deutsche Forschungsgemeinschaft (grant no. RTG2154; projects 7 and 8).

Availability of data and materials

The raw datasets analyzed in this study are available from the corresponding author upon request.

Authors’ contributions

RL, MS, JHF, CS and KH were involved in the conception and design of the study. CSF and KH planned the experimental studies, analyzed the data and wrote the manuscript. All authors have critically revised and approved the manuscript.

Ethics approval and consent to participate

Glioma samples of different malignancy grades were obtained at the Department of Neurosurgery, University Medical Center Schleswig-Holstein UKSH (Kiel, Germany) in accordance with the Declaration of Helsinki (1975) with the approval of the Ethics Committee of the University of Kiel (Kiel, Germany) and after written informed consent was obtained from the donors (file reference, D536/15).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


